Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.63 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.63 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.63 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16681873 | 0.88 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL4511148 | 0.86 | KDM4E (0.52) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL661278 | 0.86 | KDM4E (0.72) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL661538 | 0.84 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| Hydrochloric Acid SCHEMBL1421841 | 0.84 | KDM4E (0.70) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL1437502 | 0.83 | KDM4E (0.69) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL5034532 | 0.83 | L3MBTL1 (0.50) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL1570160 | 0.83 | CA12 (0.48) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL249525 | 0.83 | CA12 (0.68) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 | |
| SCHEMBL23928122 | 0.82 | CNR1 (0.49) | NPC1RAB9ASMN1; SMN2PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | claimed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | claimed |
| CN-1419538-A | Integrated process for the preparation of aromatic isocyanates and procedures for effecting the relative intermediate phases | ENICHEM SPA (IT) | 2003-05-21 | — | — | CN | claimed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-1972616-A1 | Derivatives of arylalkylcarbamates, process for their preparation and therapeutic application thereof | Sanofi-Aventis (FR) | 2008-09-24 | — | — | EP | disclosed |
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | disclosed |
| CN-1649830-A | Substituted aryl ketones | BAYER CROPSCIENCE AG (DE) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | disclosed |
| CN-1419538-A | Integrated process for the preparation of aromatic isocyanates and procedures for effecting the relative intermediate phases | ENICHEM SPA (IT) | 2003-05-21 | — | — | CN | disclosed |
| US-4487952-A | CARBONYLATION OF AROMATIC NITRO COMPOUNDS | ANIC S.P.A. (IT) | 1984-12-11 | — | — | US | disclosed |
| EP-0086018-A2 | Preparing carbamic acid esters | ANIC S.p.A. (IT) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | NPC1 450/4885RAB9A 1221/4885SMN1; SMN2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.